Embed Size (px)
Citation preview
Global Hemophilia Market Report -----------------------------------------
2016
View Report Details
Executive Summary Hemophilia refers to a set of hereditary genetic disorders that impairs the body's ability to control blood clotting,
which controls bleeding when a blood vessel is broken. People with hemophilia lack, either partially or completely, an essential clotting factor needed to form stable blood clots. In the absence of a treatment, uncontrolled internal bleeding can occur, causing stiffness, pain, severe joint damage and even death. Depending upon the coagulation factor deficiency, there are different types of hemophilia such as Hemophilia A, Hemophilia B, Hemophilia C, Von Willebrand disease and Hemophilia with Inhibitors.
Even though Hemophilia is rare bleeding disorder, the number of people affected by it has been increasing with time. While mild hemophilia is easy to diagnose especially in kids, when they learn to move and walk, and get large bruises from minute falls, severe hemophilia patients need to go for periodic transfusion of the respective factors so as to avoid the event of life-threatening bleeding episodes. Such a periodic transfusion is done through what is commonly known as the replacement therapy. With increasing sophistication and modernization of technology, demand for advanced treatment options increases, thereby making the entire market grow.
The key factors which are anticipated to drive this market include increasing penetration of recombinant factor VIII, increasing healthcare expenditure, emerging use of treatments in low income countries and increasing diagnosis rates. Some of the noteworthy progresses of this industry include the increasing adoption of prophylaxis therapy, introduction of extended half-life products and gene therapy. However, the growth of respective industry is challenged by the high cost of treatments and high reluctance by patients to switch to new treatments/products.
The report provides a comprehensive study of global hemophilia market and also major regional markets. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. The global hemophilia industry is highly competitive consisting of several large companies including the Shire Plc, Bayer Group, Pfizer Inc, Novo Nordisk etc. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.
View Report Details
Even though Hemophilia is a rare bleeding disorder, the number of people affected by it has been increasing with time.
• In the year 2015, it is recorded that the total number of people affected by hemophilia across the globe, accounts to xx thousand persons
• The global hemophilia market revenue, excluding the revenue for Von Willebrand disease, for the year 2015 is estimated to be US$xx.x billion.
• It is forecasted that the demand for prophylaxis FVIII will rise at a CAGR of x.xx% over the period 2015-2017, while the demand for recombinant FVIII will rise at a CAGR of xx.x% over the same period, amounting to xx billion units and xx billion units respectively, by the end of 2017.
Global Hemophilia Market Revenue (2015E-2020F)
Global Hemophilia Prevalence (2015)
Global FVIII Demand by Category - Volume (2015E-2017E)
Hemophilia A Hemophilia B Von Willebrand Disease
Popu
latio
n (in
Tho
usan
ds)
2015E 2016F 2017F 2018F 2019F 2020F
US$
Billio
n
2015E 2016E 2017E
Prophylaxis Recombinant
Billi
on U
nits
Due to increased use of prophylaxis in the US, as well as pharmaceutical companies’ expansion of markets, the US hemophilia market revenue has witnessed a steady growth over time
• The number of persons treated in the year 2015 is estimated to be xxx thousand, rising from xxx thousand in the previous year. Further, it is forecasted that this number of hemophilia patients treated will rise at a CAGR of x.xx% over the period spanning 2016-2020.
• The US hemophilia A market revenue is estimated to have risen from US$xxx billion in 2014 to US$xxx3 billion in 2015, with a YoY change of xx%. It is forecasted that the revenue will rise further in future at a CAGR of xx% during the five year period spanning 2016-2020, recording US$xxx1 billion in 2020F.
• It is estimated that the revenue for 2015 has increased to US$xxx.xx million, from US$551 xxx.x to grow at a CAGR of xx% during the period spanning 2016-2020, amounting to nearly US$xxx million in 2020.
The US Hemophilia A Market Revenue (2013-2020F)
The US Hemophilia Patients Treated per Year (2013-2020F)
The US Hemophilia B Market Revenue (2013-2020F)
2013 2014 2015E 2016F 2017F 2018F 2019F 2020F
Thou
sand
Per
sons
2013 2014 2015E 2016F 2017F 2018F 2019F 2020F
US$
Billio
n
2013 2014 2015E 2016F 2017F 2018F 2019F 2020F
US$
Millio
n
Recombinant FVIII has significantly higher use in developed countries, whereas emerging markets witness an increasing acceptance as they develop.
• The US Von Willebrand factor revenue is estimated to have grown from US$xxx million in 2014 to US$xxx million in 2015 and is forecasted to grow further at a CAGR of xx.2% over the period 2016-2020, amounting to US$xxx million in the year 2020F.
• The number of hemophilia A patients in Europe is estimated to have risen from xx thousand persons in 2014 to xx persons in 2015, with a YoY rise of xx.x5%.
• It is estimated that there were nearly xxx thousand patients of hemophilia B in Europe in 2015 and it is forecasted that with the number of patients in this segment will reach nearly xxx.x thousand by the year 2020.
Europe Hemophilia A Patients (2014-2020F)
The US Von Willebrand Factor Market Revenue (2013-2020F)
Europe Hemophilia B Patients (2015E-2020F)
2013 2014 2015E 2016F 2017F 2018F 2019F 2020F
US$
Millio
n
2014 2015E 2016F 2017F 2018F 2019F 2020F
Thou
sand
Per
sons
2015E 2016F 2017F 2018F 2019F 2020F
Thou
sand
Per
sons
Koncept AnalyticsCS-36, Second Floor, Ansal Plaza
Vaishali, Ghaziabad, U.P. – 201010
T. +91-120-4130959C: +91-9811715635
Contact Us:
www.konceptanalytics.com
Vikas GuptaBD Manager
These are abridged and sanitized sample pages from the comprehensive report on the “ Global Hemophilia Market ”. To know more about this report or for any customized research requirement, please contact the following:
View Report Details
